UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012197
Receipt number R000014257
Scientific Title The effect of regular exercise and regular exercise with teneligliptin on plasma GLP-1 concetration in the elderly patients with type 2 diabetes
Date of disclosure of the study information 2013/11/05
Last modified on 2017/09/08 17:51:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of regular exercise and regular exercise with teneligliptin on plasma GLP-1 concetration in the elderly patients with type 2 diabetes

Acronym

The effect of regular exercise and regular exercise with teneligliptin on plasma GLP-1 concetration in the elderly patients with type 2 diabetes

Scientific Title

The effect of regular exercise and regular exercise with teneligliptin on plasma GLP-1 concetration in the elderly patients with type 2 diabetes

Scientific Title:Acronym

The effect of regular exercise and regular exercise with teneligliptin on plasma GLP-1 concetration in the elderly patients with type 2 diabetes

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the effect of regular exercise and regular exercise with DPP-4 inhibitor (teneligliptin) on plasma IL-6 or GLP-1 concentration in the elderly patients with type 2 diabetes

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1) The changes in plasma IL-6 or GLP-1 concentration after training in the subjects with or without regular exercise
2) The changes in plasma IL-6 or GLP-1 concentration at rest in the subjects treated with or without teneligliptin, and the enchancing effect on the changes in plasma IL-6 or GLP-1 concentration by the treatment of teneligliptin

Key secondary outcomes

The change in
1) fasting blood glucose, HbA1c
2) BMI
3) serum creatinine level
4) plasma IL-6 concentration
5) plasma active GLP-1 concentration
6) intima media thickness (IMT) by carotid ultrasonography


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine Behavior,custom

Interventions/Control_1

no physical exercise habit

Interventions/Control_2

physical exercise habit

Interventions/Control_3

no physical exercise habit with treatment of 20mg/day teneligliptin

Interventions/Control_4

physical exercise habit with treatment of 20mg/day teneligliptin

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

70 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) The patients with type 2 diabetes, 70 years of age and older
2) The subjects without previous cardiovascular or respiratory diseases and abnormality of the electrocardiogram
3) The subjects with poorly-controlled diabetes (HbA1c 6.0-8.0%) by:
1. sulfonylureas with diet and exercise
2. thiazolidinediones with diet and exercise
3. alpha-glucosidase inhibitors with diet and exercise

Key exclusion criteria

1) the patients wiht type 1 diabetes
2) the subjects whose HbA1cs are below 6.0% or over 8.0%
3) the subjects who cannot reduce the dosage of sulfonylureas (using more than 2mg/day of glimepiride, 1.25mg/day of glibenclamide, 40mg of gliclazide
4) the subjects with poorly-controlled hypertension (systolic blood pressure >160mmHg)
5) the subjects with a diagonosis of effort angina, chronic heart failure(class II of NHYA classification and more) and tachyarrhythmia
6) the subjects with a diagnosis of chronic respiratory failure(class II of Hugh-Jones classification and more)
7) the subjects who cannot pedal a bike for about 30min
8) the subjects with shorter time of one leg standing (<15sec)
9) the subjects in active treatment for hypothyroidism
10) the subjects with severe liver dysfunction: more than 100IU/L of AST and ALT level
11) the subjects already enrolled in other clinical trial
12) the subjects found offensive by attending physicians for this research

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ken Sugimoto

Organization

Osaka University Graduate School of Medicine

Division name

Geriatric Medicine

Zip code


Address

2-2, Yamada-oka, Suita, Osaka

TEL

06-6879-3852

Email

sugimoto@geriat.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ken Sugimoto

Organization

Osaka University Graduate School of Medicine

Division name

Geriatri Medicine

Zip code


Address

2-2, Yamada-oka, Suita, Osaka

TEL

06-6879-3852

Homepage URL

http://www.med.osaka-u.ac.jp/pub/geriat/www/index_g.html

Email

sugimoto@geriat.med.osaka-u.ac.jp


Sponsor or person

Institute

Geriatric Medicine, Osaka University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Geriatric Medicine, Osaka University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 11 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 09 Month 20 Day

Date of IRB


Anticipated trial start date

2013 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 11 Month 01 Day

Last modified on

2017 Year 09 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014257


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name